ArticleClinical, cosmetic and investigational dermatology2026
Localized Bullous Pemphigoid of the Scalp and Face with Suspected Vulvar Involvement: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Localized bullous pemphigoid (LBP) is a form of bullous pemphigoid (BP) confined to a limited anatomical area. Classification becomes less certain when clinically similar lesions occur at a distant site without site-specific immunopathologic confirmation. We report immunopathologically supported scalp/facial BP-spectrum disease with a temporally associated but unconfirmed vulvar eruption. Case Presentation: A 51-year-old woman presented with a 3-month history of pruritic erythema and tense bullae on the scalp and face and a 1-month history of erythematous scaly plaques with hemorrhagic bullous lesions in the vulvar region. Scalp histopathology showed a subepidermal blister with eosinophil-rich inflammation, and direct immunofluorescence (DIF) of perilesional scalp skin showed linear IgG and C3 deposition along the basement membrane zone. Infectious studies of the vulvar eruption were negative. Anti-BP180/230 serology, indirect immunofluorescence, salt-split skin studies, and anti-type VII collagen antibody testing were unavailable. Vulvar biopsy and DIF were not performed; therefore, vulvar BP could not be confirmed. With systemic and topical corticosteroids plus adjunctive minocycline, no new bullae developed by day 5, and the lesions markedly improved within 2 weeks. Methylprednisolone was subsequently tapered from 40 mg/day to a maintenance dose of 4 mg/day; minocycline and topical corticosteroids were discontinued after sustained clinical improvement. At 6 months, the disease remained clinically controlled on methylprednisolone 4 mg/day, with no new bullae or clinically evident recurrence. No treatment-related adverse events were observed. Conclusion: The findings support localized BP/BP-spectrum disease of the scalp and face, while the vulvar eruption remains unconfirmed. The parallel treatment response is supportive but not diagnostic of vulvar BP. When feasible, lesions at sensitive sites should undergo site-specific biopsy and DIF. If biopsy is declined or impractical, pretreatment morphology should be carefully documented, diagnostic uncertainty should be acknowledged, and follow-up should assess for scarring and additional mucosal involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.